Doxifluridine
Furtulon · Antimetabolite (oral 5-FU prodrug)
5'-DFUR prodrug; class-level TMA risk plus a real renal-clearance component warranting caution in renal impairment.
RAS(ON) multi-selective inhibitor
Rasonque · DARX
RAS(ON) multi-selective inhibitor · approved 2026 · 7 citations
Describes how this page is sourced, not how dangerous the drug is. Thinly sourced means fewer of the sourcing signals are met — not that the agent is kidney-safe. A rule-based summary, not a formal certainty appraisal.
The first RAS(ON) inhibitor, which blocks mutant and wild-type RAS alike. Its kidney story is mostly the gut's - creatinine rose in 24% against 9% on chemotherapy, beside 67% diarrhea - with one renal-limited thrombotic microangiopathy in the label.
Atlas fields gathered in one place, each linked to the section with its full text and sources. Educational, not medical advice.
Signature lesion
Daraxonrasib carries a renal laboratory signal against an active comparator, and the FDA label is the only source for it. In RASolute 302's laboratory table, creatinine increased from baseline in 24% of patients on daraxonrasib (grade 3-4 0.8%) against 9% on physician's-choice chemotherapy (grade 3-4 0%), with denominators of 234-237 and 207-208. Electrolyte losses ran alongside it: sodium decreased in 36% (grade 3-4 6%) against 30%, and magnesium in 34% against 22%, while potassium decreased less often than on chemotherapy (20% against 33%). Among clinically important adverse reactions under 10%, the label lists renal-limited thrombotic microangiopathy in 0.4% of the 241 patients treated - one patient. Diarrhea (67%, grade 3-4 7%) and vomiting (42%) were more frequent than on chemotherapy (44% and 25%), and diarrhea was the commonest serious adverse reaction (3.7%). Neither published RASolute 302 abstract reports a renal row.Source: Creatinine increased 24% all-grade / 0.8% grade 3-4 on daraxonrasib (n=234-237) versus 9% / 0% on chemotherapy (n=207-208); renal-limited TMA 0.4% (N=241) - FDA label, RASolute 302
This agent's kidney lesions ordered by prominence — the #1 signature lesion first, then secondary and rare patterns. Cited incidence is shown where a citable figure exists; otherwise the tier stands qualitatively.
Renal hypoperfusion from capillary leak and cytokine storm — IL-2 and CAR-T cytokine release syndrome.
Renal electrolyte derangement — magnesium/potassium/calcium wasting (cisplatin, anti-EGFR antibodies) or retention (FGFR-inhibitor hyperphosphatemia, tumor-lysis hyperkalemia/hyperphosphatemia).
Endothelial injury with microvascular thrombi, hemolysis and thrombocytopenia — gemcitabine, mitomycin C, anti-VEGF.
Tap a signature to trace where it strikes the nephron.
Representative incidence
Functional / pre-renal — reduced perfusion upstream of the nephron; no single structural segment is injured.
Prerenal / Hemodynamic AKI: functional / pre-renal, no single structural segment injured.
Prerenal / Hemodynamic AKI
Renal hypoperfusion from capillary leak and cytokine storm — IL-2 and CAR-T cytokine release syndrome.
Oral RAS(ON) multi-selective tri-complex inhibitor. Daraxonrasib binds the intracellular chaperone cyclophilin A, and the binary complex then binds the active, GTP-bound state of RAS, blocking its interaction with downstream effectors and promoting GTP hydrolysis to the inactive state. It inhibits wild-type and mutant KRAS, NRAS and HRAS, which is why its toxicities resemble broad RAS-pathway blockade (skin, mucosa, gut) rather than a single-mutant inhibitor's. Given as 300 mg orally once daily, with dose reductions to 200 mg and then 150 mg for adverse reactions.
7 primary references — trials, cohorts, mechanism, and reviews. Citation metadata via PubMed / NLM.
Primary (non–case-report) references per year — a proxy for how actively the agent's renal literature is accruing. Recent years are highlighted. Reflects curation depth, not a systematic bibliometric count.
Everything below is FAERS — adverse events someone chose to report, about 10 of them for this agent. Nobody counts the patients who were fine, so none of these numbers is an incidence, a risk, or a rate: they describe what gets reported, shaped by a drug's fame, its indication, and who was watching. How these numbers work.
10 reports is below the 50 this atlas requires before quoting a percentage, so the counts are shown instead of shares.
Reported with a death outcome
too few reports to express as a share
Reported with hospitalization
too few reports to express as a share
Reports per year
Reports received per year, 2015–2026 · most recent year is partial.
Bars rank systems by summed reaction-term mentions (a report counts once per term it names) — an ordinal “more vs less reported” cue, not a tally of distinct reports. Renal & urinary first. As of 2026-11-15.
Each recommendation below is this atlas's faithful summary of the source, not a quotation from it — follow the PubMed link for the wording the society published. Summaries may be superseded; consult the current full text and individualize to the patient.
General onco-nephrology references
Where Daraxonrasib sits in nephrotoxicity space — each dot is an anti-cancer agent, positioned so neighbors share a kidney-injury phenotype. Its 6 closest are filled and lead to a numbered marker, matching the numbered cards below.
Furtulon · Antimetabolite (oral 5-FU prodrug)
5'-DFUR prodrug; class-level TMA risk plus a real renal-clearance component warranting caution in renal impairment.
Mifurol · Antimetabolite (oral 5-FU prodrug)
Lipophilic oral 5-FU prodrug (Japan); class-level renal risk; hallmark toxicity is leukoencephalopathy not nephropathy.
UFT · Antimetabolite (oral 5-FU prodrug)
Oral tegafur+uracil; rare fluoropyrimidine-class TMA/HUS (often with mitomycin C), otherwise kidney-sparing.
Lumoxiti · Immunotoxin (anti-CD22 PE38)
Boxed warning for capillary-leak syndrome and hemolytic-uremic syndrome / TMA.
Komzifti · Menin inhibitor
2025 NPM1-mutated AML menin inhibitor; differentiation syndrome and tumor lysis.
Tecelra · MAGE-A4 TCR-T cell therapy
First TCR-T cell therapy for a solid tumor; CRS-associated hemodynamic AKI.
Nearest agents by kidney-injury phenotype (shared injuries, nephron target, severity, class) — a similarity approximation, not a claim of shared drug identity or mechanism.